Date Filed | Type | Description |
07/17/2023 |
4
| Ali-Jackson Kamil (Director) has filed a Form 4 on PDS Biotechnology Corp
Txns:
| Granted 9,000 options to buy
@ $5.13, valued at
$46.2k
|
|
07/12/2023 |
4
| Ali-Jackson Kamil (Director) has filed a Form 4 on RIGEL PHARMACEUTICALS INC
Txns:
| Granted 25,000 shares
@ $0 Granted 30,000 options to buy
@ $1.32, valued at
$39.6k
|
|
06/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/05/2022 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Exercised 3,875 restricted stock units
@ $0 Exercised 27,905 restricted stock units
@ $0 Exercised 6,638 restricted stock units
@ $0 Exercised 7,100 restricted stock units
@ $0 |
|
12/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/17/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
11/22/2021 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Gifted 7,500 shares
@ $0 |
|
06/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/17/2020 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 498 shares
@ $4.59, valued at
$2.3k
Exercised 1,734 restricted stock units
@ $0 |
|
06/25/2020 |
4
| Ali-Jackson Kamil (Director) has filed a Form 4 on PDS Biotechnology Corp
Txns:
| Granted 3,033 options to buy
@ $1.45, valued at
$4.4k
|
|
06/03/2020 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 9,534 shares
@ $1.32, valued at
$12.6k
Exercised 33,188 restricted stock units
@ $0 |
|
03/04/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/24/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/24/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
02/04/2020 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 1,318 shares
@ $1.28, valued at
$1.7k
Exercised 3,875 restricted stock units
@ $0 |
|
12/20/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/18/2019 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 497 shares
@ $1.8, valued at
$894.6 Exercised 1,733 restricted stock units
@ $0 |
|
03/04/2019 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Granted 68,700 restricted stock units
@ $0 |
|
02/05/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/20/2018 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 306 shares
@ $6.3, valued at
$1.9k
Exercised 1,075 restricted stock units
@ $0 |
|
12/18/2018 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 493 shares
@ $7.31, valued at
$3.6k
Exercised 1,733 restricted stock units
@ $0 |
|
06/12/2018 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Sold 100 shares
@ $20, valued at
$2k
Sold 4,900 shares
@ $20, valued at
$98k
|
|
05/21/2018 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Sold 10,000 shares
@ $20, valued at
$200k
|
|
05/09/2018 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 1,974 shares
@ $18.1, valued at
$35.7k
Exercised 6,933 restricted stock units
@ $0 |
|
03/20/2018 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Acquired 9,018 shares
@ $0 |
|
02/05/2018 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Granted 54,000 options to buy
@ $22.09, valued at
$1.2M
Granted 15,500 restricted stock units
@ $0 |
|
12/21/2017 |
4
| Ali-Jackson Kamil (Chief Legal Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 527 shares
@ $24.23, valued at
$12.8k
Paid exercise price by delivering 327 shares
@ $24.12, valued at
$7.9k
Exercised 1,733 restricted stock units
@ $0 Exercised 1,075 restricted stock units
@ $0 |
|
|